Regulatory
FDA Approves AstraZeneca’s Etcamah for Breast Cancer — Guided by a Blood Test for Resistance
Camizestrant is the first cancer therapy cleared based on spotting a resistance mutation in circulating tumor DNA — letting doctors switch treatment before scans show the cancer is growing again.